Ironwood Pharmaceuticals, Inc. (IRWD), a GI-focused healthcare company, today announced that the company and its collaborators will present clinical data for IW-3718, and both clinical and non-clinical data for linaclotide during Digestive Disease Week (DDW) being held in San Diego, CA, May 18 through May 21, 2019.
Devastating fungal disease tackled with antimicrobial and anchor peptide combo.
Scientists have fused two peptides to create a pesticide that protects legume crops from Asian soybean rust. One peptide kills the fungus behind the disease, and the other acts as a sticker to bind the system to leaves.
BALTIMORE, April 28, 2019 /PRNewswire/ -- Novo Nordisk today announced the results from the ELLIPSE trial which examined efficacy and safety and demonstrated superiority of Victoza® (liraglutide) injection 1.8 mg vs placebo in reducing blood sugar in children and adolescents aged 10-17 with type 2 diabetes.1 ELLIPSE is the first phase 3 trial completed in over a decade in children and adolescen......
Premenopausal women treated with letrozole as neoadjuvant endocrine therapy for HER2-negative breast cancer attained faster and more sustained ovarian function suppression with degarelix than with triptorelin, according to results of a randomized phase 2 trial published in Journal of Clinical Oncology.
To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer.
The United States Pharmacopeial Convention (USP) Therapeutic Peptides Expert Panel was formed in 2013 to evaluate quality attributes for synthetic peptides based on currently available regulatory guidance and expectations.
.jpg)
.jpg)
.jpg)
.jpg)
